Pharmacological and Therapeutic Potential of Garlic ( Allium sativum ): Integrating Phytochemistry, Molecular Mechanisms, and Clinical and Preclinical Evidence
- 1Department of Pharmacy Marie Stopes International Ethiopia (MSIE) Ambo Ethiopia
Abstract
Garlic ( Allium sativum ) is a medicinal plant with diverse pharmacological properties and therapeutic potential in metabolic, cardiovascular, hepatic, immune, inflammatory, infectious, and neoplastic disorders. However, comprehensive integration of clinical and preclinical evidence remains limited. This review synthesized randomized controlled trials, crossover studies, therapeutic clinical investigations, and experimental animal studies evaluating garlic supplementation. Allicin was identified as the principal intermediate precursor generating numerous bioactive organosulfur compounds. Clinical evidence demonstrated reductions in systolic blood pressure of 5.2%–10.5% and diastolic blood pressure of 4.0%, decreases in LDL cholesterol of 11.8%–14.2% and total cholesterol of 7.6%–14.2%, and increases in HDL cholesterol of 11.5%. Fasting glucose decreased by 7.01 mg/dL, and HbA1c by 0.66%. Inflammatory markers, including TNF‐α and C‐reactive protein, declined by up to 24.7%, whereas antioxidant capacity increased. Preclinical studies demonstrated reduced tumor growth, improved renal function, enhanced epithelial regeneration, and increased survival in experimental infection models. Garlic demonstrates consistent therapeutic benefits across multiple conditions. Nevertheless, additional high‐quality, large‐scale clinical trials are required to establish optimal dosing, long‐term safety, and clinical efficacy.
Related
- 1,8-Cineole (Eucalyptol) in Neurodegeneration: From Pharmacological Mechanisms to Therapeutic Applications.
- Phytochemistry, pharmacology, safety, and applications of Buddleja globosa Hope [Scrophulariaceae]: a systematic review from bioactive metabolites and mechanisms to translational perspectives
- Drug-Development Potential of Muntingia calabura L.: A Systematic Review of Ethnopharmacological Use, Pharmacological Potency, Preclinical Evidence, and Plant-Mediated Nanotechnology
- Editorial: Potential therapeutic targets in alcohol use disorder: insights from recent preclinical studies
- Therapeutic potential of oncolytic viruses in hematopoietic malignancies: from preclinical insights to clinical realities
BibTeX
@article{bereda2026pharmacological,
title = {{Pharmacological and Therapeutic Potential of Garlic ( Allium sativum ): Integrating Phytochemistry, Molecular Mechanisms, and Clinical and Preclinical Evidence}},
author = {Gudisa Bereda},
journal = {ChemistryOpen},
year = {2026},
month = oct,
doi = {10.1002/open.70321},
url = {https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/open.70321},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Pharmacological and Therapeutic Potential of Garlic ( Allium sativum ): Integrating Phytochemistry, Molecular Mechanisms, and Clinical and Preclinical Evidence
AU - Gudisa Bereda
PY - 2026
DA - 2026/10/27
JO - ChemistryOpen
DO - 10.1002/open.70321
UR - https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/open.70321
AB - Garlic ( Allium sativum ) is a medicinal plant with diverse pharmacological properties and therapeutic potential in metabolic, cardiovascular, hepatic, immune, inflammatory, infectious, and neoplastic disorders. However, comprehensive integration of clinical and preclinical evidence remains limited. This review synthesized randomized controlled trials, crossover studies, therapeutic clinical investigations, and experimental animal studies evaluating garlic supplementation. Allicin was identified as the principal intermediate precursor generating numerous bioactive organosulfur compounds. Clinical evidence demonstrated reductions in systolic blood pressure of 5.2%–10.5% and diastolic blood pressure of 4.0%, decreases in LDL cholesterol of 11.8%–14.2% and total cholesterol of 7.6%–14.2%, and increases in HDL cholesterol of 11.5%. Fasting glucose decreased by 7.01 mg/dL, and HbA1c by 0.66%. Inflammatory markers, including TNF‐α and C‐reactive protein, declined by up to 24.7%, whereas antioxidant capacity increased. Preclinical studies demonstrated reduced tumor growth, improved renal function, enhanced epithelial regeneration, and increased survival in experimental infection models. Garlic demonstrates consistent therapeutic benefits across multiple conditions. Nevertheless, additional high‐quality, large‐scale clinical trials are required to establish optimal dosing, long‐term safety, and clinical efficacy.
SN - 2191-1363
SN - 2191-1363
ER -